Page last updated: 2024-08-17

bromodeoxyuridine and Benign Monoclonal Gammopathies

bromodeoxyuridine has been researched along with Benign Monoclonal Gammopathies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boireau, S; Bouhya, S; Cartron, G; Ceballos, P; Hose, D; Klein, B; Moreaux, J; Requirand, G; Robert, N; Seckinger, A; Vincent, L1
Ballieux, RE; Bast, BJ; Boom, SE; Lokhorst, HM1

Other Studies

2 other study(ies) available for bromodeoxyuridine and Benign Monoclonal Gammopathies

ArticleYear
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
    Cytometry. Part B, Clinical cytometry, 2019, Volume: 96, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Cohort Studies; Diagnosis, Differential; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Ki-67 Antigen; Lymphocyte Count; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Prognosis; Progression-Free Survival; Recurrence; Staining and Labeling; Transplantation, Autologous

2019
Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique.
    British journal of haematology, 1986, Volume: 64, Issue:2

    Topics: Bone Marrow; Bromodeoxyuridine; Cell Cycle; DNA; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Thymidine; Time Factors

1986